Capricor Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Linda Marbán
- Full Time Employees
- 231
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10865 Road to the Cure San Diego CA United States of America 92121
- IPO Date
- Feb 13, 2007
- CIK
- 0001133869
- Website
- capricor.com
- Similar Companies
- Business
- Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company that develops transformative cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy and other rare diseases with high unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company focuses on allogeneic cardiosphere-derived cells and engineered exosomes, targeting primary markets in the United States, Japan, and Europe through strategic partnerships. Its lead product candidate, deramiocel (also known as CAP-1002), comprises cardiosphere-derived cells that provide immunomodulatory, anti-fibrotic, anti-inflammatory, and regenerative effects via exosome-mediated mechanisms, including microRNAs that alter gene expression to reduce inflammation and promote tissue repair in dystrophinopathies; deramiocel has completed the Phase 3 HOPE-3 trial, demonstrating statistically significant improvements in skeletal and cardiac function, building on durable benefits observed in the HOPE-2 trial and its over 48-month open-label extension. The company advances a proprietary StealthX exosome platform for precision-engineered therapeutics, including targeted delivery of RNA, proteins, small molecules, and vaccines; this encompasses preclinical and early-stage programs such as an NIAID-funded Phase 1 exosome-based vaccine candidate for infectious diseases with topline data expected in early 2026, alongside CAP-2003 for DMD and broader applications in inflammatory and regenerative medicine. Capricor maintains license agreements with institutions including Johns Hopkins University, University of Rome, Cedars-Sinai Medical Center, and Life Technologies to support its cell and exosome technologies. In recent developments, Capricor announced positive topline results from the pivotal Phase 3 HOPE-3 study of deramiocel in December 2025, prompting plans for a Biologics License Application resubmission to the FDA by year-end incorporating this data to address prior manufacturing observations from a Complete Response Letter; the company expanded its partnership with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. in 2024 to include exclusive commercialization and distribution rights for deramiocel in Europe alongside the existing U.S. and Japan agreements, which provide upfront payments, development and sales milestones up to approximately $89 million, and double-digit royalties. Capricor reports a cash position of approximately $99 million as of Q3 2025, sufficient to fund operations into late 2026 amid commercial launch preparations for potential 2026 market introduction and ongoing exosome platform advancement.
What's Going On With Capricor Therapeutics Stock On Friday?
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
Caprock Announces Closing of Private Placement
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.
Caprock Announces Proposed Private Placement
Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 25,000 Shares of Stock
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 61,265 Shares
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 53,735 Shares of Stock